Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
August 8, 2024 4:17 PM EDTGoldman Sachs analyst Paul Choi raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $12.00 (from $10.00) while maintaining a Neutral rating.
The analyst comments "Topline beat for Voquezna reflects commercial progress though sales remain nominal. PHAT announced its 2Q24 financial results this... More
